Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Up 8.1% in December

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 530,200 shares, an increase of 8.1% from the November 30th total of 490,400 shares. Based on an average daily volume of 28,200 shares, the days-to-cover ratio is presently 18.8 days. Currently, 9.0% of the company’s stock are short sold.

Greenwich LifeSciences Stock Up 2.9 %

Greenwich LifeSciences stock traded up $0.32 during trading hours on Wednesday, hitting $11.23. The stock had a trading volume of 42,190 shares, compared to its average volume of 39,041. The stock’s 50-day moving average price is $13.29 and its 200-day moving average price is $14.27. The stock has a market capitalization of $147.62 million, a P/E ratio of -14.04 and a beta of 1.61. Greenwich LifeSciences has a 12-month low of $8.00 and a 12-month high of $21.44.

Hedge Funds Weigh In On Greenwich LifeSciences

A number of hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers purchased a new stake in Greenwich LifeSciences during the 2nd quarter valued at $117,000. Bank of New York Mellon Corp bought a new position in shares of Greenwich LifeSciences during the second quarter valued at $264,000. Garden State Investment Advisory Services LLC purchased a new stake in shares of Greenwich LifeSciences during the third quarter valued at $253,000. Barclays PLC boosted its position in shares of Greenwich LifeSciences by 323.3% during the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after buying an additional 6,538 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Greenwich LifeSciences by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock worth $1,919,000 after buying an additional 5,861 shares in the last quarter. 4.16% of the stock is currently owned by hedge funds and other institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.